Low-dose cadmium induces lymphangiogenesis through activation of the STAT3 signaling pathway - 29/05/24
, Ju Liu b, ⁎ 
Abstract |
Cadmium (Cd) is a widespread environmental toxicant that poses significant threat to public health. After intake, Cd is distributed throughout the body via blood and lymphatic circulation. However, the effect of Cd on lymphatic vessels has not been revealed. In this study, mice were exposed to 10 μM cadmium chloride through drinking water immediately after corneal alkali burn. In vivo analyses showed that Cd treatment enhances the alkali burn-induced corneal lymphangiogenesis, which is characterized by increased expression of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), prospero-related homeobox 1 (PROX-1) and vascular endothelial growth factor receptor 3 (VEGFR3). In vitro, the proliferation and migration of human dermal lymphatic endothelial cells (HDLECs) are increased by 1 μM Cd treatment, while inhibited by 10 μM Cd treatment. At a concentration of 1 μM, Cd specifically induces phosphorylation of signal transducer and activator of transcription 3 (STAT3), but has no effect on the MAPK, AKT, or NF-κB signaling pathway. In the presence of the STAT3 inhibitor STATTIC, Cd fails to induce HDLECs proliferation and migration. In addition, Cd upregulates VEGFR3 expression and its gene promoter activity in a STAT3-dependent manner. Our study suggests that low-dose Cd promotes lymphangiogenesis through activation of the STAT3 signaling pathway.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Low-dose cadmium (Cd) enhances alkali burn-induced lymphangiogenesis in mice. |
• | Cd induces lymphatic endothelial cell (LEC) proliferation and migration in vitro. |
• | Cd activates the STAT3 pathway, not the MAPKs or AKT pathway in LECs. |
• | Cd induces VEGFR3 expression through activation of the STAT3 pathway in LECs. |
Keywords : Cadmium, Lymphatic endothelial cells, Lymphangiogenesis, STAT3, VEGFR3
Plan
Vol 175
Article 116741- juin 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
